Gene therapy for the prevention of vein graft disease

Translational Research

Volumn 161, Issue 4, 2013, Pages 321-338

  Southerland, Kevin W ^a   Frazier, Sarah B ^a   Bowles, Dawn E ^a   Milano, Carmelo A ^a   Kontos, Christopher D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LENTIVIRUS VECTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NAKED DNA; NANOPARTICLE; OLIGODEOXYNUCLEOTIDE; PADGEM PROTEIN; PLASMID DNA; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; THROMBOMODULIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ARTERIAL CIRCULATION; CELL MIGRATION; CELL PROLIFERATION; DNA MODIFICATION; ENDOTHELIUM INJURY; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; LENTIVIRINAE; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; STEM CELL; VEIN GRAFT DISEASE; VEIN THROMBOSIS;

EID: 84875190717     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.12.003     Document Type: Review

References (179)

1. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association Circulation 125 2012 188 197
2. J.A. Bittl Advances in coronary angioplasty N Engl J Med 335 1996 1290 1302
3. S.N. Haider, E.G. Kavanagh, and M. Forlee Two-year outcome with preferential use of infrainguinal angioplasty for critical ischemia J Vasc Surg 43 2006 504 512
4. D.J. Adam, J.D. Beard, and T. Cleveland Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial Lancet 366 2005 1925 1934
5. P.P. Goodney, A.W. Beck, J. Nagle, H.G. Welch, and R.M. Zwolak National trends in lower extremity bypass surgery, endovascular interventions, and major amputations J Vasc Surg 50 2009 54 60
6. M. Hata, A. Sezai, and T. Niino What is the optimal management for preventing saphenous vein graft diseases?: early results of intravascular angioscopic assessment Circ J 71 2007 286 287
7. P. Parang, and R. Arora Coronary vein graft disease: pathogenesis and prevention Can J Cardiol 25 2009 e57 e62
8. M.S. Conte, T.J. Lorenz, D.F. Bandyk, A.W. Clowes, G.L. Moneta, and B.L. Seely Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure Vasc Endovascular Surg 39 2005 15 23
9. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics-2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
10. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators N Engl J Med 336 1997 153 162
11. S.J. Shah, D.D. Waters, and P. Barter Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery J Am Coll Cardiol 51 2008 1938 1943
12. M. Domanski, X. Tian, and J. Fleg Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial Am J Cardiol 102 2008 1023 1027
13. G.M. Fitzgibbon, H.P. Kafka, A.J. Leach, W.J. Keon, G.D. Hooper, and J.R. Burton Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years J Am Coll Cardiol 28 1996 616 626
14. J.H. Alexander, G. Hafley, and R.A. Harrington Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial JAMA 294 2005 2446 2454
15. R.G. Favaloro Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique Ann Thorac Surg 5 1968 334 339
16. H.K. Eltzschig, and C.D. Collard Vascular ischaemia and reperfusion injury British Medical Bulletin 70 2004 71 86
17. V.V. Shuvaev, and V.R. Muzykantov Targeted modulation of reactive oxygen species in the vascular endothelium J Control Release 153 2011 56 63
18. M.R. Dashwood, and J.C. Tsui 'No-touch' saphenous vein harvesting improves graft performance in patients undergoing coronary artery bypass surgery: A journey from bedside to bench Vascul Pharmacol 2012 10.1016/j.vph.2012.07.008
19. A.H. Sepehripour, O.A. Jarral, A.R. Shipolini, and D.J. McCormack Does a 'no-touch' technique result in better vein patency? Interact Cardiovasc Thorac Surg 13 2011 626 630
20. M.G. Davies, M.L. Klyachkin, H. Dalen, M.F. Massey, E. Svendsen, and P.O. Hagen The integrity of experimental vein graft endothelium-implications on the etiology of early graft failure Eur J Vasc Surg 7 1993 156 165
21. J. Cheng, and J. Du Mechanical stretch simulates proliferation of venous smooth muscle cells through activation of the insulin-like growth factor-1 receptor Arterioscler Thromb Vasc Biol 27 2007 1744 1751
22. H. Song, A.L. Mowbray, M.C. Sykes, and H. Jo Emerging role of IGF-1R in stretch-induced neointimal hyperplasia in venous grafts Arterioscler Thromb Vasc Biol 27 2007 1679 1681
23. T. Kozai, M. Eto, Z. Yang, H. Shimokawa, and T.F. Luscher Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway Cardiovasc Res 68 2005 475 482
24. H. Tanaka, G.K. Sukhova, and S.J. Swanson Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury Circulation 88 1993 1788 1803
25. T.A. Springer Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm Cell 76 1994 301 314
26. M.S. Lee, E.M. David, R.R. Makkar, and J.R. Wilentz Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system J Pathol 203 2004 861 870
27. T.T. Huynh, M.G. Davies, M.A. Thompson, M.D. Ezekowitz, P. Hagen, and B.H. Annex Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts J Vasc Surg 33 2001 400 407
28. M.G. Davies, and P.O. Hagen Pathobiology of intimal hyperplasia Br J Surg 81 1994 1254 1269
29. S.M. Schwartz Smooth muscle migration in atherosclerosis and restenosis J Clin Invest 100 1997 S87 S89
30. A.K. Mitra, D.M. Gangahar, and D.K. Agrawal Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia Immunol Cell Biol 84 2006 115 124
31. J.H. Lardenoye, M.R. de Vries, and C.W. Lowik Accelerated atherosclerosis and calcification in vein grafts: a study in APOE*3 Leiden transgenic mice Circ Res 91 2002 577 584
32. S. Wan, S.J. George, C. Berry, and A.H. Baker Vein graft failure: current clinical practice and potential for gene therapeutics Gene Ther 19 2012 630 636
33. J.A. Hata, J.A. Petrofski, and J.N. Schroder Modulation of phosphatidylinositol 3-kinase signaling reduces intimal hyperplasia in aortocoronary saphenous vein grafts J Thorac Cardiovasc Surg 129 2005 1405 1413
34. A. Santel, M. Aleku, and O. Keil A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium Gene Ther 13 2006 1222 1234
35. T. Miyake, M. Aoki, and S. Shiraya Inhibitory effects of NFκB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model J Mol Cell Cardiol 41 2006 431 440
36. R. Morishita, G.H. Gibbons, and M. Horiuchi A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo Proc Natl Acad Sci U S A 92 1995 5855 5859
37. J. Sun, J. Zheng, and K.H. Ling Preventing intimal thickening of vein grafts in vein artery bypass using STAT-3 siRNA J Transl Med 10 2012 2
38. M.J. Mann, A.D. Whittemore, and M.C. Donaldson Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial Lancet 354 1999 1493 1498
39. J. Panyam, and V. Labhasetwar Biodegradable nanoparticles for drug and gene delivery to cells and tissue Adv Drug Deliv Rev 55 2003 329 347
40. M.P. Desai, V. Labhasetwar, E. Walter, R.J. Levy, and G.L. Amidon The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent Pharmaceut Res 14 1997 1568 1573
41. M.P. Desai, V. Labhasetwar, G.L. Amidon, and R.J. Levy Gastrointestinal uptake of biodegradable microparticles: effect of particle size Pharmaceut Res 13 1996 1838 1845
42. J. Panyam, W.Z. Zhou, S. Prabha, S.K. Sahoo, and V. Labhasetwar Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery FASEB J 16 2002 1217 1226
43. L.A. Guzman, V. Labhasetwar, and C. Song Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty Circulation 94 1996 1441 1448
44. V. Labhasetwar, J. Bonadio, S.A. Goldstein, and J.R. Levy Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model Colloid Surface B 16 1999 281 290
45. S. Hanafusa, Y. Matsusue, and T. Yasunaga Biodegradable plate fixation of rabbit femoral shaft osteotomies. A comparative study Clin Orthopaed Relat Res 1995 262 271
46. J. Davda, and V. Labhasetwar Characterization of nanoparticle uptake by endothelial cells International journal of pharmaceutics 233 2002 51 59
47. H. Cohen-Sacks, Y. Najajreh, and V. Tchaikovski Novel PDGFβR antisense encapsulated in polymeric nanospheres for the treatment of restenosis Gene Ther 9 2002 1607 1616
48. W. Walther, and U. Stein Viral vectors for gene transfer: a review of their use in the treatment of human diseases Drugs 60 2000 249 271
49. A.H. Schulick, G. Vassalli, and P.F. Dunn Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity J Clin Invest 99 1997 209 219
50. Y. Yang, F.A. Nunes, K. Berencsi, E.E. Furth, E. Gonczol, and J.M. Wilson Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy Proc Natl Acad Sci U S A 91 1994 4407 4411
51. K.M. Channon, H.S. Qian, and S.A. Youngblood Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function Circ Res 82 1998 1253 1262
52. K.D. Newman, P.F. Dunn, and J.W. Owens Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia J Clin Invest 96 1995 2955 2965
53. A.R. Brooks, R.N. Harkins, P. Wang, H.S. Qian, P. Liu, and G.M. Rubanyi Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle J Gene Med 6 2004 395 404
54. W. Doerfler, A. Hoeveler, and B. Weisshaar Promoter inactivation or inhibition by sequence-specific methylation and mechanisms of reactivation Cell Biophys 15 1989 21 27
55. M. Groudine, R. Eisenman, and H. Weintraub Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation Nature 292 1981 311 317
56. R.J. Guzman, P. Lemarchand, R.G. Crystal, S.E. Epstein, and T. Finkel Efficient gene transfer into myocardium by direct injection of adenovirus vectors Circ Res 73 1993 1202 1207
57. S. Kochanek, P.R. Clemens, K. Mitani, H.H. Chen, S. Chan, and C.T. Caskey A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase Proc Natl Acad Sci U S A 93 1996 5731 5736
58. R.J. Parks, L. Chen, M. Anton, U. Sankar, M.A. Rudnicki, and F.L. Graham A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal Proc Natl Acad Sci U S A 93 1996 13565 13570
59. S. Wen, S. Graf, P.G. Massey, and D.A. Dichek Improved vascular gene transfer with a helper-dependent adenoviral vector Circulation 110 2004 1484 1491
60. E. Marshall Gene therapy death prompts review of adenovirus vector Science 286 1999 2244 2245
61. S. Lehrman Virus treatment questioned after gene therapy death Nature 401 1999 517 518
62. N.B. Wasala, J.-H. Shin, and D. Duan The evolution of heart gene delivery vectors J Gene Med 13 2011 557 565
63. M.H. Eslami, S.P. Gangadharan, X. Sui, K.K. Rhynhart, R.O. Snyder, and M.S. Conte Gene delivery to in situ veins: differential effects of adenovirus and adeno-associated viral vectors J Vasc Surg 31 2000 1149 1159
64. M. Gruchala, S. Bhardwaj, and K. Pajusola Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors J Gene Med 6 2004 545 554
65. E.C. Svensson, D.J. Marshall, and K. Woodard Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors Circulation 99 1999 201 205
66. J.A. Wagner, T. Reynolds, and M.L. Moran Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus Lancet 351 1998 1702 1703
67. M.G. Kaplitt, A. Feigin, and C. Tang Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial Lancet 369 2007 2097 2105
68. J.D. Finn, T.C. Nichols, and N. Svoronos The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy Blood 120 2012 4521 4523
69. D. Pankajakshan, T.O. Makinde, and R. Gaurav Successful transfection of genes using AAV-2/9 vector in swine coronary and peripheral arteries J Surg Res 175 2012 169 175
70. L.M. Work, H. Buning, and E. Hunt Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses Mol Ther 13 2006 683 693
71. L.M. Work, S.A. Nicklin, and N.J. Brain Development of efficient viral vectors selective for vascular smooth muscle cells Mol Ther 9 2004 198 208
72. S.A. Nicklin, H. Buening, and K.L. Dishart Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells Mol Ther 4 2001 174 181
73. D.M. McCarty Self-complementary AAV vectors; advances and applications Mol Ther 16 2008 1648 1656
74. D. Cefai, E. Simeoni, and K.M. Ludunge Multiply attenuated, self-inactivating lentiviral vectors efficiently transduce human coronary artery cells in vitro and rat arteries in vivo J Mol Cell Cardiol 38 2005 333 344
75. L. Naldini, U. Blomer, and P. Gallay In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 272 1996 263 267
76. Z. Qian, M. Haessler, and J.A. Lemos Targeting vascular injury using Hantavirus-pseudotyped lentiviral vectors Mol Ther 13 2006 694 704
77. T. Sakuma, M.A. Barry, and Y. Ikeda Lentiviral vectors: basic to translational Biochem J 443 2012 603 618
78. S. Philippe, C. Sarkis, and M. Barkats Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo Proc Natl Acad Sci U S A 103 2006 17684 17689
79. M. Handa, W. Li, K. Morioka, A. Takamori, N. Yamada, and A. Ihaya Adventitial delivery of platelet-derived endothelial cell growth factor gene prevented intimal hyperplasia of vein graft J Vasc Surg 48 2008 1566 1574
80. J. Wang, K. Liu, L. Shen, H. Wu, and H. Jing Small interfering RNA to c-myc inhibits vein graft restenosis in a rat vein graft model J Surg Res 169 2011 e85 e91
81. J.A. Petrofski, J.A. Hata, and T.R. Gehrig Gene delivery to aortocoronary saphenous vein grafts in a large animal model of intimal hyperplasia J Thorac Cardiovasc Surg 127 2004 27 33
82. J.A. Petrofski, J.A. Hata, and M.L. Williams A Gβγ inhibitor reduces intimal hyperplasia in aortocoronary saphenous vein grafts J Thorac Cardiovasc Surg 130 2005 1683 1690
83. M.S. Khaleel, T.A. Dorheim, and M.J. Duryee High-pressure distention of the saphenous vein during preparation results in increased markers of inflammation: a potential mechanism for graft failure Ann Thorac Surg 93 2012 552 558
84. M.J. Mann, G.H. Gibbons, and H. Hutchinson Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues Proc Natl Acad Sci U S A 96 1999 6411 6416
85. G. Vassalli, R. Agah, R. Qiao, C. Aguilar, and D.A. Dichek A mouse model of arterial gene transfer: antigen-specific immunity is a minor determinant of the early loss of adenovirus-mediated transgene expression Circ Res 85 1999 e25 e32
86. M. Sugimoto, D. Yamanouchi, and K. Komori Therapeutic approach against intimal hyperplasia of vein grafts through endothelial nitric oxide synthase/nitric oxide (eNOS/NO) and the Rho/Rho-kinase pathway Surg Today 39 2009 459 465
87. H. Weaver, N. Shukla, D. Ellinsworth, and J.Y. Jeremy Oxidative stress and vein graft failure: a focus on NADH oxidase, nitric oxide and eicosanoids Curr Opin Pharmacol 12 2012 160 165
88. S. Moncada, and A. Higgs The L-arginine-nitric oxide pathway N Engl J Med 329 1993 2002 2012
89. S. Lamas, P.A. Marsden, G.K. Li, P. Tempst, and T. Michel Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform Proc Natl Acad Sci U S A 89 1992 6348 6352
90. E. Gkaliagkousi, and A. Ferro Nitric oxide signalling in the regulation of cardiovascular and platelet function Front Biosci 16 2011 1873 1897
91. D.G. Cable, T. O'Brien, I.J. Kullo, R.S. Schwartz, H.V. Schaff, and V.J. Pompili Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries Cardiovasc Res 35 1997 553 559
92. D.G. Cable, J.A. Caccitolo, and N. Caplice The role of gene therapy for intimal hyperplasia of bypass grafts Circulation 100 1999 II392 II396
93. T. Matsumoto, K. Komori, and Y. Yonemitsu Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff J Vasc Surg 27 1998 135 144
94. S. Ohta, K. Komori, Y. Yonemitsu, T. Onohara, T. Matsumoto, and K. Sugimachi Intraluminal gene transfer of endothelial cell-nitric oxide synthase suppresses intimal hyperplasia of vein grafts in cholesterol-fed rabbit: a limited biological effect as a result of the loss of medial smooth muscle cells Surgery 131 2002 644 653
95. O. Belton, D. Byrne, D. Kearney, A. Leahy, and D.J. Fitzgerald Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis Circulation 102 2000 840 845
96. D.J. Crutchley, L.B. Conanan, and B.G. Que Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells J Pharmacol Exp Ther 271 1994 446 451
97. S. Hara, R. Morishita, and Y. Tone Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells Biochem Biophys Res Commun 216 1995 862 867
98. K.K. Wu Regulation of prostaglandin H synthase-1 gene expression Adv Exp Med Biol 400A 1997 121 126
99. H.C. Eichstaedt, Q. Liu, and Z. Chen Gene transfer of COX-1 improves lumen size and blood flow in carotid bypass grafts J Surg Res 161 2010 162 167
100. P. Zoldhelyi, J. McNatt, and X.M. Xu Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene Circulation 93 1996 10 17
101. M.H. Zou, C. Shi, and R.A. Cohen Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite J Clin Invest 109 2002 817 826
102. T.W. Hein, E. Qamirani, Y. Ren, and L. Kuo C-reactive protein impairs coronary arteriolar dilation to prostacyclin synthase activation: role of peroxynitrite J Mol Cell Cardiol 47 2009 196 202
103. C.M. Schmalfuss, L.Y. Chen, J.N. Bott, E.D. Staples, and J.L. Mehta Superoxide anion generation, superoxide dismutase activity, and nitric oxide release in human internal mammary artery and saphenous vein segments J Cardiovasc Pharmacol Ther 4 1999 249 257
104. C.A. Hamilton, G. Berg, M. McIntyre, A.R. McPhaden, J.L. Reid, and A.F. Dominiczak Effects of nitric oxide and superoxide on relaxation in human artery and vein Atherosclerosis 133 1997 77 86
105. Y. Shi, S. Patel, and K.L. Davenpeck Oxidative stress and lipid retention in vascular grafts: comparison between venous and arterial conduits Circulation 103 2001 2408 2413
106. T.T. Huynh, M.G. Davies, M.J. Trovato, L. Barber, H.J. Safi, and P.O. Hagen Reduction of lipid peroxidation with intraoperative superoxide dismutase treatment decreases intimal hyperplasia in experimental vein grafts J Surg Res 84 1999 223 232
107. P. Turunen, H.L. Puhakka, and T. Heikura Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits Hum Gene Ther 17 2006 405 414
108. S.Q. He, Y.H. Zhang, and S.K. Venugopal Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice Liver Transpl 12 2006 1869 1879
109. T. Van-Assche, V. Huygelen, M.J. Crabtree, and C. Antoniades Gene therapy targeting inflammation in atherosclerosis Curr Pharm Des 17 2011 4210 4223
110. W. Durante Targeting heme oxygenase-1 in vascular disease Curr Drug Targets 11 2010 1504 1516
111. R. Pakala Coagulation factor Xa synergistically interacts with serotonin in inducing vascular smooth muscle cell proliferation Cardiovasc Radiat Med 4 2003 69 76
112. E. Bretschneider, M. Braun, A. Fischer, M. Wittpoth, E. Glusa, and K. Schror Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells Thromb Haemost 84 2000 499 505
113. R.T. Pyo, Y. Sato, N. Mackman, and M.B. Taubman Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration Thromb Haemost 92 2004 451 458
114. D. Collen, H.R. Lu, and J.M. Stassen Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis Thromb Haemost 71 1994 95 102
115. J.J. Belch, G.D. Lowe, J.G. Pollock, C.D. Forbes, and C.R. Prentice Low dose heparin in the prevention of deep-vein thrombosis after aortic bifurcation graft surgery Thromb Haemost 42 1980 1429 1433
116. M. Gosling, J. Golledge, R.J. Turner, and J.T. Powell Arterial flow conditions downregulate thrombomodulin on saphenous vein endothelium Circulation 99 1999 1047 1053
117. A.Y. Kim, P.L. Walinsky, and F.D. Kolodgie Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure Circ Res 90 2002 205 212
118. N. Tabuchi, M. Shichiri, and A. Shibamiya Nonviral in vivo thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins Eur J Cardiothorac Surg 26 2004 995 1001
119. E. Torsney, U. Mayr, Y. Zou, W.D. Thompson, Y. Hu, and Q. Xu Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection Circ Res 94 2004 1466 1473
120. S. Goldman, J. Copeland, and T. Moritz Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: results of a VA Cooperative study Circulation 89 1994 1138 1143
121. A.C. Thomas, M.J. Wyatt, and A.C. Newby Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer Thromb Haemost 102 2009 145 152
122. P.R. Hilfiker, J.M. Waugh, and J.J. Li-Hawkins Enhancement of neointima formation with tissue-type plasminogen activator J Vasc Surg 33 2001 821 828
123. X. Jiang, X. Liu, and K. Zhang Experimental study of tissue-type plasminogen activator gene to prevent vein grafts stenosis J Huazhong Univ Sci Technolog Med Sci 26 2006 314 316
124. C. Cerletti, C. Tamburrelli, B. Izzi, F. Gianfagna, and G. de Gaetano Platelet-leukocyte interactions in thrombosis Thromb Res 129 2012 263 266
125. J.S. Pober, and G. Tellides Participation of blood vessel cells in human adaptive immune responses Trends Immunol 33 2012 49 57
126. D. Vestweber Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium Immunol Rev 218 2007 178 196
127. M.R. Williams, V. Azcutia, G. Newton, P. Alcaide, and F.W. Luscinskas Emerging mechanisms of neutrophil recruitment across endothelium Trends Immunol 32 2011 461 469
128. R.A. Wolff, J.J. Tomas, D.A. Hullett, V.E. Stark, N. van Rooijen, and J.R. Hoch Macrophage depletion reduces monocyte chemotactic protein-1 and transforming growth factor-beta1 in healing rat vein grafts J Vasc Surg 39 2004 878 888
129. V.K. Stark, J.R. Hoch, T.F. Warner, and D.A. Hullett Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia Arterioscler Thromb Vasc Biol 17 1997 1614 1621
130. F. Cipollone, M. Marini, and M. Fazia Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty Arterioscler Thromb Vasc Biol 21 2001 327 334
131. S. Hokimoto, Y. Oike, and T. Saito Increased expression of monocyte chemoattractant protein-1 in atherectomy specimens from patients with restenosis after percutaneous transluminal coronary angioplasty Circ J 66 2002 114 116
132. Y.J. Zhang, B.J. Rutledge, and B.J. Rollins Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis J Biol Chem 269 1994 15918 15924
133. Y. Zhang, and B.J. Rollins A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer Mol Cell Biol 15 1995 4851 4855
134. A. Schepers, D. Eefting, and P.I. Bonta Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo Arterioscler Thromb Vasc Biol 26 2006 2063 2069
135. H. Tatewaki, K. Egashira, S. Kimura, T. Nishida, S. Morita, and R. Tominaga Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation J Vasc Surg 45 2007 1236 1243
136. D. Eefting, I. Bot, and M.R. de Vries Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice J Vasc Surg 50 2009 152 160
137. B. Pamukcu, G.Y. Lip, and E. Shantsila The nuclear factor-κ B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease Thromb Res 128 2011 117 123
138. T. Shintani, Y. Sawa, and T. Takahashi Intraoperative transfection of vein grafts with the NFκB decoy in a canine aortocoronary bypass model: a strategy to attenuate intimal hyperplasia Ann Thorac Surg 74 2002 1132 1137 discussion 7-8
139. D. Rossi, and A. Zlotnik The biology of chemokines and their receptors Annu Rev Immunol 18 2000 217 242
140. A. Alcami, J.A. Symons, P.D. Collins, T.J. Williams, and G.L. Smith Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus J Immunol 160 1998 624 633
141. C.A. Bursill, S. Cai, K.M. Channon, and D.R. Greaves Adenoviral-mediated delivery of a viral chemokine binding protein blocks CC-chemokine activity in vitro and in vivo Immunobiology 207 2003 187 196
142. C.A. Bursill, R.P. Choudhury, Z. Ali, D.R. Greaves, and K.M. Channon Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice Circulation 110 2004 2460 2466
143. Z.A. Ali, C.A. Bursill, and Y. Hu Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice Circulation 112 2005 I235 I241
144. H.L. Puhakka, P. Turunen, and M. Gruchala Effects of vaccinia virus anti-inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits In Vivo 19 2005 515 521
145. C.A. Bursill, J.L. Cash, K.M. Channon, and D.R. Greaves Membrane-bound CC chemokine inhibitor 35K provides localized inhibition of CC chemokine activity in vitro and in vivo J Immunol 177 2006 5567 5573
146. R. Gotoh, J. Suzuki, and H. Kosuge E-selectin blockade decreases adventitial inflammation and attenuates intimal hyperplasia in rat carotid arteries after balloon injury Arterioscler Thromb Vasc Biol 24 2004 2063 2068
147. A. Jabs, E. Okamoto, J. Vinten-Johansen, G. Bauriedel, and J.N. Wilcox Sequential patterns of chemokine- and chemokine receptor-synthesis following vessel wall injury in porcine coronary arteries Atherosclerosis 192 2007 75 84
148. E. Okamoto, T. Couse, and H. De Leon Perivascular inflammation after balloon angioplasty of porcine coronary arteries Circulation 104 2001 2228 2235
149. R.C. Siow, and A.T. Churchman Adventitial growth factor signalling and vascular remodelling: potential of perivascular gene transfer from the outside-in Cardiovasc Res 75 2007 659 668
150. A.C. Newby Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture Physiol Rev 85 2005 1 31
151. S.J. George, C.T. Lloyd, G.D. Angelini, A.C. Newby, and A.H. Baker Inhibition of Late Vein Graft Neointima Formation in Human and Porcine Models by Adenovirus-Mediated Overexpression of Tissue Inhibitor of Metalloproteinase-3 Circulation 101 2000 296 304
152. S.J. George, S. Wan, J. Hu, R. MacDonald, J.L. Johnson, and A.H. Baker Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy Circulation 124 2011 S135 S142
153. E. Wilson, Q. Mai, K. Sudhir, R.H. Weiss, and H.E. Ives Mechanical strain induces growth of vascular smooth muscle cells via autocrine action of PDGF J Cell Biol 123 1993 741 747
154. M.R. Dashwood, and A. Loesch Surgical damage of the saphenous vein and graft patency J Thorac Cardiovasc Surg 133 2007 274 275
155. M.J. Mann, G.H. Gibbons, and R.S. Kernoff Genetic engineering of vein grafts resistant to atherosclerosis Proc Natl Acad Sci U S A 92 1995 4502 4506
156. J. Huang, and C.D. Kontos Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN Arterioscler Thromb Vasc Biol 22 2002 745 751
157. J. Huang, X.L. Niu, A.M. Pippen, B.H. Annex, and C.D. Kontos Adenovirus-mediated intra-arterial delivery of PTEN inhibits neointimal hyperplasia Arterioscler Thromb Vasc Biol 25 2005 354 358
158. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
159. L.E. Rameh, and L.C. Cantley The role of phosphoinositide 3-kinase lipid products in cell function J Biol Chem 274 1999 8347 8350
160. J.E. Sousa, M.A. Costa, and A.C. Abizaid Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up Circulation 104 2001 2007 2011
161. J.E. Sousa, M.A. Costa, and A. Abizaid Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study Circulation 107 2003 24 27
162. A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 2001 807 826
163. T. Maehama, and J.E. Dixon The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 273 1998 13375 13378
164. R.A. Weinberg The retinoblastoma protein and cell cycle control Cell 81 1995 323 330
165. A. Ehsan, M.J. Mann, G. Dell'Acqua, and V.J. Dzau Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy J Thorac Cardiovasc Surg 121 2001 714 722
166. A. Ehsan, M.J. Mann, G. Dell'Acqua, K. Tamura, R. Braun-Dullaeus, and V.J. Dzau Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease Circulation 105 2002 1686 1692
167. M.J. Mann, G.H. Gibbons, and P.S. Tsao Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts J Clin Invest 99 1997 1295 1301
168. M.J. Mann, KR, and V.J. Dzau Vein graft gene therapy using E2F decoy oligonucleotides: target gene inhibition in human veins and long term resistance to atherosclerosis in rabbits Surg Forum 1997 242 244
169. Late-Breaking Clinical Trial Abstracts Circulation 104 2001 1b 4b
170. M.S. Conte, D.F. Bandyk, and A.W. Clowes Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery J Vasc Surg 43 2006 742 751 discussion 51
171. C. Attwooll, E. Lazzerini Denchi, and K. Helin The E2F family: specific functions and overlapping interests EMBO J 23 2004 4709 4716
172. J.L. Chong, P.L. Wenzel, and M.T. Saenz-Robles E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells Nature 462 2009 930 934
173. J.G. Motwani, and E.J. Topol Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention Circulation 97 1998 916 931
174. L. Zhang, N.J. Freedman, L. Brian, and K. Peppel Graft-extrinsic cells predominate in vein graft arterialization Arterioscler Thromb Vasc Biol 24 2004 470 476
175. P. Fogelstrand, K. Osterberg, and E. Mattsson Reduced neointima in vein grafts following a blockage of cell recruitment from the vein and the surrounding tissue Cardiovasc Res 67 2005 326 332
176. R.D. Lopes, R.H. Mehta, and G.E. Hafley Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery Circulation 125 2012 749 756
177. C.D. Owens, P.M. Ridker, and M. Belkin Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery J Vasc Surg 45 2007 2 9 discussion
178. A.C. Thomas Animal models for studying vein graft failure and therapeutic interventions Curr Opin Pharmacol 12 2012 121 126
179. M.A. Kuliszewski, J. Kobulnik, J.R. Lindner, D.J. Stewart, and H. Leong-Poi Vascular gene transfer of SDF-1 promotes endothelial progenitor cell engraftment and enhances angiogenesis in ischemic muscle Mol Ther 19 2011 895 902